Tumor necrosis factor α and melfalan-based hyperthermic isolated limb perfusion in locally advanced extremity soft tissue sarcomas and melanomas;Tratamiento regional del sarcoma y melanoma localmente avanzado de la extremidad mediante la perfusión aislada con tumor necrosis factor α y melfalan asociada a hipertermia

Cirugia Espanola

Volumn 90, Issue 2, 2012, Pages 114-120

  Alegre, José Farre ^a   Duarte, Maritza ^a   Sureda González, Manuel ^a   Bretcha Boix, Pere ^a   Dussan, Carlos ^a   Ballester, Antonio ^a   Crespo, Aurora ^a   Brugarolas Masllorens, Antonio ^a  

^a USP Hospital San Jaime   (Spain)

Author keywords

Chemohyperthermic; In transit metastasis; Isolated limb perfusion; Melanoma; Soft tissue sarcoma; TNF

Indexed keywords

ALKYLATING AGENT; MELPHALAN; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ARM; ARTICLE; FEMALE; HUMAN; HYPERTHERMIC THERAPY; LEG; LIMB SALVAGE; MALE; MELANOMA; METHODOLOGY; MIDDLE AGED; REGIONAL PERFUSION; RETROSPECTIVE STUDY; SARCOMA; SOFT TISSUE TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; ARM; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; LEG; LIMB SALVAGE; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; RETROSPECTIVE STUDIES; SARCOMA; SOFT TISSUE NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84857048816     PISSN: 0009739X     EISSN: 1578147X     Source Type: Journal    
DOI: 10.1016/j.ciresp.2011.10.012     Document Type: Article

References (33)

1. Creech O., Krementz E.T., Ryan R.F., Winblad J.N. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958, 148:616-632.
2. Grunhagen D.J., de Wilt J.H., van Geel A.N., Verhoef C., Eggermont A.M. Isolated limb perfusion with TNF-alpha and melphalan in locally advanced soft tissue sarcomas of the extremities. Recent Results Cancer Res 2009, 179:257-270.
3. Calvo E., Arcas R., Crespo A., Brugarolas A. Perfusión de extremidad aislada en Oncología. Rev Oncol 2003, 5:128-138.
4. Sureda M., Farre J., Crespo A., Molina M., Bretcha P., Ballester A., et al. Tratamiento con perfusión aislada de extremidad (ILP) con TNF y melfalán de las recurrencias de melanoma localizadas en extremidades: acreditación, indicaciones y técnica. Oncologia 2006, 29(suppl 1):110-114.
5. AJCC Cancer Staging Handbook. 7th edition. Springer-Verlag: New York; 2010.
6. Noorda E.M., Vrouenraets B.C., Nieweg O.E., van Geel A.N., Eggermont A.M., Kroon B.B. Prognostic factors for survival after isolated limb perfusion for malignant melanoma. Eur J Surg Oncol 2003, 29:916-921.
7. Hayes A.J., Neuhaus S.J., Clark M.A., Thomas J.M. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma. Ann Surg Oncol 2007, 14:230-238.
8. Grunhagen D.J., de Wilt J.H., ten Hagen T.L., Eggermont A.M. Technology insight: Utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. Nat Clin Pract Oncol 2006, 3:94-103.
9. Eggermont A.M., van Geel A.N., de Wilt J.H., ten Hagen T.L. The role of isolated limb perfusion for melanoma confined to the extremities. Surg Clin North Am 2003, 83:371-384.
10. Eggermont A.M. Isolated limb perfusion in the management of locally advanced extremity soft tissue sarcoma. Surg Oncol Clin N Am 2003, 12:469-483.
11. Lejeune F.J., Kroon B.B., Di Filippo F., Hoekstra H.J., Santinami M., Liénard D., et al. Isolated limb perfusion: the European experience. Surg Oncol Clin N Am 2001, 10:821-832.
12. Eggermont A.M.M., de Wilt J.H.W., ten Hagen T.L.M. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncology 2003, 4:429-437.
13. Stam T.C., Swaak A.J.G., de Vries M.R., ten Hagen T.L., Eggermont A.M. Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage. Annals of Surgical Oncology 2000, 7:268-275.
14. Santillan A.A., Delman K.A., Beasley G.M., Mosca P.J., Hochwald S.N., Grobmyer S.R., et al. Predictive factor of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma a multiinstitucional analysis. Ann Surg Oncol 2009, 9:2570-2578.
15. Beasley G.M., Claude A., Petersen R.P., McMahon N.S., Padussis J., Mosca P.J., et al. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg 2009, 5:706-715.
16. Vrouenraets B.C., Eggermont A.M., Hart A.A., Klaase J.M., van Geel A.N., Nieweg O.E., et al. Regional toxicity after isolated limb perfusion with mephalan and tumor necrosis factor-alpha vs toxicity after mephalan alone. Eur J Surg Oncol 2001, 27:390-395.
17. Nishino M., Jagannathan J.P., Ramaiya N.H., Van den Abbeele A.D. Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know. AJR Am J Roentgend 2010, 2:281-289.
18. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
19. Montero L.A., Perez A.D., López M.J.A. Multidisciplinary management of soft tissue sarcomas. Clin Transl Oncol 2010, 12:543-553.
20. Wray CJ, Benjamin RS, Hunt KK, Cormier JN, Ross MI, Feig BW. Isolated limb perfusion for unresectable extremity sarcoma. Cancer. 2011;117:3235-41.
21. Gimbel M.I., Delman K.A., Zager J.S. Therapy for unresectable recurrent and in-transit extremity melanoma. Cancer Control 2008, 15:225-232.
22. Sureda M., Rebollo J., Vázquez B., Farré J., Molina M., Crespo A., et al. Tratamiento del melanoma con infusión de interleukina-2 a dosis altas. Oncología 2006, 29(Suppl 1):105-109.
23. Senzer N., Mani S., Rosemurgy A., Nemunaitis J., Cunningham C., Guha C., et al. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol 2004, 22:592-601.
24. Rasmussen H., Rasmussen C., Lempicki M., Durham R., Brough D., King C.R., et al. TNFerade Biologic: preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene. Cancer Gene Ther 2002, 9:951-957.
25. Moreno-Ramirez D., Cruz-Merino L., Ferrandiz L., Villegas-Portero R., Nieto-Garcia A. Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety. The Oncologist 2010, 4:416-427.
26. Eggermont A.M., ten Hagen T.L. Isolated limb perfusion for extremity soft-tissue sarcomas, in-transit metastases, and other unresectable tumors: credits, debits, and future perspectives. Curr Oncol Rep 2001, 3:359-367.
27. Nooijen P.T., Eggermont A.M., Schalkwijk L., Henzen-Logmans S., de Waal R.M., Ruiter D.J. Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: a clinical and histopathological study of the delayed-type reaction pattern. Cancer Res 1998, 58:4880-4887.
28. Grunhagen D.J., de Wilt J.H., Graveland W.J., van Geel A.N., Eggermont A.M. The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma. Cancer 2006, 106:156-162.
29. Takkenberg R.B., Vrouenraets B.C., van Geel A.N., Nieweg O.E., Noorda E.M., Eggermont A.M., et al. Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients. J Surg Oncol 2005, 91:107-111.
30. Grunhagen D.J., van Etten B., Brunstein F., Graveland W.J., van Geel A.N., de Wilt J.H., et al. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure. Ann Surg Oncol 2005, 12:609-615.
31. Noorda E.M., Vrouenraets B.C., Nieweg O.E., van Geel A.N., Eggermont A.M., Kroon B.B. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion. Eur J Surg Oncol 2006, 32:318-324.
32. Vrouenraets B.C., Hart G.A., Eggermont A.M., Klaase J.M., van Geel B.N., Nieweg O.E., et al. Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J Am Coll Surg 1999, 188:522-530.
33. Wieberdink K., Benckhuijsen C., Braat R.P., van Slooten E.A., Olthuis G.A. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982, 18:905-910.